Ablynx Archives -

Goofy lama pulling face. Funny llama animal sticking tongue out

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after

Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out

https://pharmaphorum.com/news/can-llama-antibodies-beat-covid-19-belgiums-exevir-raises-23m-euros-to-find-out/

Ablynx drug fails in mid-stage lupus trial

Richard Staines Ablynx, Sanofi 0 Comment

Ablynx’s vobarilizumab has failed in a mid-stage trial in lupus, with the biotech’s multi-billion buyout from Sanofi just

Ablynx drug fails in mid-stage lupus trial

https://pharmaphorum.com/news/ablynxs-vobarilizumab-fails-mid-stage-lupus-trial/

Market Access/ News/ News/ R&D/ Top stories/ UK & Europe

Sanofi says biotech acquisitions will help overcome diabetes decline

Andrew McConaghie Ablynx, Bioverativ, haeomophilia, Sanofi 0 Comment

Sanofi has just spent $16 billion on acquiring Bioverativ and Ablynx – and yesterday’s Q4 results revealed why

Sanofi says biotech acquisitions will help overcome diabetes decline

https://pharmaphorum.com/news/sanofi-says-biotech-acquisitions-will-help-overcome-diabetes-decline/

Diabetes/ Market Access/ News/ News

Novo Nordisk undeterred after losing out on Ablynx takeover

Andrew McConaghie Ablynx, Diabetes, Novo Nordisk, Ozempic 0 Comment

After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.

Novo Nordisk undeterred after losing out on Ablynx takeover

https://pharmaphorum.com/news/novo-nordisk-undeterred-losing-ablynx-takeover/

News/ News/ R&D/ R&D/ UK & Europe

Sanofi steals in to buy Ablynx for €3.9 billion

Andrew McConaghie Ablynx, European biotech, M&A, Mergers and acquisitions, Sanofi 0 Comment

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which

Sanofi steals in to buy Ablynx for €3.9 billion

https://pharmaphorum.com/news/sanofi-steals-buy-ablynx-e3-9-billion/

M&A/ News

Novo Nordisk must increase Ablynx bid, says shareholder

Richard Staines Ablynx, M&A, Novo Nordisk 0 Comment

Novo Nordisk must up its bid to take over Belgian biotech Ablynx, after the company’s largest shareholder reportedly

Novo Nordisk must increase Ablynx bid, says shareholder

https://pharmaphorum.com/news/novo-nordisk-must-increase-ablynx-bid-says-shareholder/

News/ R&D/ Top stories/ US

After more encouraging data, Ablynx to file first drug with FDA

Richard Staines Ablynx, aTTP, Biotech, European biotech, Rare diseases 0 Comment

New trial data will be included in US and EU filings

After more encouraging data, Ablynx to file first drug with FDA

https://pharmaphorum.com/news/ablynx-prepares-us-filing-caplacizumab-attp/

News/ R&D/ UK & Europe

Ablynx soars after blood clot trial success

Richard Staines Ablynx, European biotech, Rare diseases 0 Comment

European regulators are already reviewing caplacizumab

Ablynx soars after blood clot trial success

https://pharmaphorum.com/news/phase-3-results-confirm-efficacy-ablynx-attp-drug/

News/ R&D

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

Richard Staines Ablynx, inflammatory diseases, R&D, Rheumatoid arthritis, Sanofi 0 Comment

Collaboration will develop drugs for inflammatory diseases

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

https://pharmaphorum.com/news/ablynx-sanofi-sign-potential-2-4-bn-euros-rd-deal/

Trending

Ablynx

Login